Modality
ERT
MOA
KRASG12Ci
Target
LAG-3
Pathway
mTOR
DravetRB
Development Pipeline
Preclinical
~Dec 2013
→ ~Mar 2015
Phase 1
~Jun 2015
→ ~Sep 2016
Phase 2
~Dec 2016
→ ~Mar 2018
Phase 3
~Jun 2018
→ ~Sep 2019
NDA/BLA
~Dec 2019
→ ~Mar 2021
Approved
Jun 2021
→ Feb 2026
ApprovedCurrent
NCT07793748
2,512 pts·Dravet
2021-06→2026-02·Terminated
2,512 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2026-02-082mo agoPh3 Readout· Dravet
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
Approved
Termina…
Catalysts
Ph3 Readout
2026-02-08 · 2mo ago
Dravet
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07793748 | Approved | Dravet | Terminated | 2512 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| BMR-9762 | BioMarin | Phase 3 | Aβ | |
| Niralucimab | Ionis | Phase 1 | ALK |